IGF-1 LR3 · Research brief

Does IGF 1 LR3 Increase Testosterone? (Research Data)

Real Peptides Research TeamEditorial

Updated September 25, 202610 min read

60 WORDS

Short answer

Two questions dominate almost every search log around this peptide: whether IGF-1 LR3 raises testosterone, and what the best time to take IGF LR3 is. Both share the same uncomfortable answer. Neither has a verifiable published answer, because Long R3 IGF-1 has never been approved or trialled as a human therapeutic, and it isn't supplied for that purpose by us…

Key takeaways

There is no published human evidence that IGF-1 LR3 increases testosterone, and the compound has no reported androgen receptor affinity.
Leydig cells express IGF-1 receptors, and cultured-cell research suggests IGF-1 can potentiate LH-stimulated steroidogenesis, which is a mechanism observation rather than a systemic result.
Long R3 IGF-1 differs from native IGF-1 by a 13-amino-acid N-terminal extension and an arginine-for-glutamic-acid swap at position 3, taking the chain from 70 to 83 residues.
Reduced IGFBP affinity is the single structural fact that explains the extended biological availability reported across the literature.
Nobody has defined the best time to take IGF LR3 because no human trial has ever been conducted to define one.
Time-to-effect ranges from minutes for receptor phosphorylation in vitro to weeks for tissue-level endpoints in preclinical models, so the question is meaningless without a named endpoint.
Before-and-after imagery carries no control, no blinding, and no assay, and should never be treated as evidence.

We supply research-grade peptides to laboratories and read the analytical data on every batch before it ships. What follows is what the structural chemistry and the receptor literature actually support, and where the internet has filled a gap with invention.

Does IGF 1 LR3 increase testosterone?

There's no published human evidence that IGF-1 LR3 increases testosterone. Long R3 IGF-1 is a modified 83-amino-acid analogue of insulin-like growth factor 1 that signals through the IGF-1 receptor, not the androgen receptor. Research in cultured Leydig cells suggests IGF-1 signalling can amplify LH-stimulated steroidogenesis, but that's isolated cell data, not a systemic outcome in a living organism.

The common misreading is treating the growth hormone axis and the reproductive axis as one system that a single molecule can nudge in either direction. They're linked, but they're separately regulated, and a compound with high affinity for one receptor family tells you very little about the other. This piece covers the receptor biology behind the testosterone question, the structural modifications that make LR3 behave so differently from native IGF-1, and why questions about timing and time-to-results collapse once you ask which endpoint is being measured.

Where the testosterone question comes from, and what the receptor data shows

IGF-1 LR3 has no reported affinity for the androgen receptor, so it cannot raise testosterone the way an exogenous androgen or an aromatase inhibitor does. The confusion comes from collapsing two endocrine systems into one. The somatotropic axis runs from hypothalamic GHRH to pituitary growth hormone to hepatic IGF-1 production. The hypothalamic-pituitary-gonadal axis runs from GnRH to luteinising hormone and follicle-stimulating hormone to the Leydig and theca cells that actually synthesise steroid hormones.

Those axes do talk to each other. Leydig cells express the IGF-1 receptor, and work in cultured rodent Leydig cell preparations suggests IGF-1 signalling can potentiate LH-driven steroidogenesis. That is a meaningful observation about a mechanism. It is not a finding that an injected IGF-1 analogue raises serum testosterone in a whole organism, and the literature doesn't make that leap.

There's a countervailing mechanism too. Circulating IGF-1 exerts negative feedback at the pituitary and hypothalamus, suppressing endogenous growth hormone secretion. So exogenous IGF-1 analogues alter the somatotropic axis in a direction that has little to do with androgen output.

The closest regulated comparator is mecasermin (Increlex), recombinant human IGF-1, which the FDA approved for severe primary IGF-1 deficiency. Its labelled outcomes concern linear growth and hypoglycaemia risk. Testosterone elevation isn't among them.

Across the enquiries our team fields about this compound, the testosterone claim almost always traces back to a forum post rather than a paper. That's the whole evidentiary chain.

Why the best time to take IGF LR3 has no published answer

No regulatory body, clinical guideline, or peer-reviewed human trial has ever defined the best time to take IGF LR3, and none is likely to. Long R3 IGF-1 is a research chemical for in vitro and preclinical laboratory work, not a drug product. What the literature does describe with precision is why this analogue behaves nothing like the native hormone.

Native human IGF-1 is a single 70-amino-acid chain of roughly 7.6 kDa. Long R3 IGF-1 is 83 amino acids and roughly 9.1 kDa, carrying two deliberate modifications: a 13-residue extension on the N-terminus, and arginine substituted for glutamic acid at position 3. Both changes sharply reduce affinity for the insulin-like growth factor binding proteins, IGFBP-1 through IGFBP-6.

That matters enormously. Almost all native IGF-1 in circulation travels bound in a ternary complex with IGFBP-3 and the acid-labile subunit, which acts as both a reservoir and a clearance brake. Unbound native IGF-1 disappears within minutes. LR3 largely escapes that sequestration, which is why its biological availability is described in the literature as substantially prolonged relative to native IGF-1, with exact figures varying by species and assay.

Here's the nuance most write-ups miss: the Arg3 substitution gets all the credit, but the N-terminal extension does comparable work. Together they're the reason LR3 became the standard IGF supplement in industrial cell culture. The IGFBPs that cultured cells secrete into their own medium can't mop it up.

Which is exactly why queries like 'IGF-1 LR3 before or after workout' or 'best time to inject IGF 1 LR3' rest on a premise the molecule's own design contradicts. We don't publish timing protocols. There aren't any to publish.

What 'how long to see results' means when nobody names the endpoint

Questions about how long to see results from IGF 1 LR3 have no single answer, because the timescale depends entirely on which endpoint is being measured, and those endpoints differ by orders of magnitude. Receptor-level events and tissue-level events are separated by weeks.

In vitro, IGF-1 receptor autophosphorylation and activation of the downstream PI3K/Akt and MAPK cascades occur within minutes of exposure. Measurable shifts in protein synthesis rates and glucose uptake in cultured cells register over hours. Myoblast proliferation and differentiation studies read out over days. Tissue-level endpoints in preclinical animal models, things like nitrogen balance or organ and muscle mass, are typically assessed over weeks of a study period.

So when someone asks how long does it take for IGF 1 LR3 to work, the honest reply is another question: work on what, measured how?

This is also why 'IGF-1 LR3 before and after' content is analytically worthless. A photograph is not an endpoint. It carries no control arm, no blinding, no assay, and no account of diet, training load, hydration, lighting, or the other compounds that almost always accompany it in those accounts. Our team has reviewed a great deal of this material, and the pattern never changes: the confident claims come with no data, and the actual data comes with no confident claims.

The information here is educational and describes laboratory research only. Long R3 IGF-1 is not a medicine, and nothing above should be read as guidance for use in humans or animals.

Native IGF-1 versus Long R3 IGF-1: a structural comparison

The practical differences between the two molecules explain nearly every downstream question about persistence and potency. This table summarises what the structural and handling literature establishes.

Property	Native IGF-1	IGF-1 LR3 (Long R3)	Bottom Line for Laboratory Work
Chain length and mass	70 amino acids, roughly 7.6 kDa	83 amino acids, roughly 9.1 kDa	The extra mass is the 13-residue N-terminal extension, not a different active core
Position 3 residue	Glutamic acid	Arginine substituted for glutamic acid	A single point change that meaningfully weakens binding-protein docking
IGFBP affinity	High affinity for IGFBP-1 through IGFBP-6	Markedly reduced affinity across the binding protein family	LR3 stays free in medium instead of being sequestered by cell-secreted IGFBPs
Persistence in circulation	Unbound fraction cleared within minutes; bound complex acts as reservoir	Reported as substantially longer, with values differing by species and assay	Study design must account for exposure that outlasts a single timepoint
Regulatory status	Recombinant form approved as mecasermin for a narrow deficiency indication	Not approved as a drug anywhere; research use only	Never describe or supply LR3 as a therapeutic product
Handling	Lyophilised peptide, cold chain dependent	Lyophilised peptide, cold chain dependent	Both degrade with temperature excursion; storage discipline governs batch reliability

What If: laboratory handling and sourcing scenarios

What if a vial arrives without a certificate of analysis?

Treat the material as unverified and don't enter it into a study. A certificate should report identity and purity by HPLC and confirm mass by mass spectrometry against the expected molecular weight for the 83-residue sequence. Without it, you have no evidence the vial contains Long R3 IGF-1 rather than native IGF-1, a truncated fragment, or excipient. Every batch we ship is accompanied by its own analytical documentation, and we publish those records rather than describing them.

What if lyophilised material sits at ambient temperature after delivery?

Log the excursion, including its duration and the approximate temperature, before deciding anything. Lyophilised peptides are generally stored frozen at around minus 20 degrees Celsius for long-term stability, and reconstituted solutions are refrigerated at 2 to 8 degrees Celsius. Short ambient exposure during transit is normal and usually tolerated in the dry state. Prolonged warmth is the problem, because protein denaturation and aggregation aren't visible to the eye and won't announce themselves in your data until the results look inexplicable.

What if a reconstituted solution looks cloudy or shows particulates?

Stop and discard rather than filter and proceed. Cloudiness in a peptide solution usually signals aggregation, precipitation, or microbial contamination, and none of those conditions produce reliable experimental data. Peptide solutions should be clear and colourless after gentle dissolution. Vigorous shaking is a frequent culprit, since the shear forces at the air-liquid interface denature protein far more efficiently than most people expect.

What if a model organism shows no measurable change in the first several days?

Check whether the assay you're running can detect change on that timescale before concluding the compound is inactive. Receptor-level signalling events resolve in minutes, while anthropometric or tissue-mass endpoints in preclinical studies need weeks of accumulation to exceed measurement noise. A null result at day three against a tissue endpoint says nothing about the compound. It says the measurement window was mismatched to the biology.

What if someone asks about using a research peptide in an animal at home?

Redirect them. Research-grade peptides are supplied for controlled laboratory work, not for companion animals, and anyone with questions about an animal's health should talk to their veterinarian rather than acting on a forum protocol. A veterinarian can assess the animal, order appropriate diagnostics, and prescribe products manufactured and labelled for veterinary use.

The blunt truth about timing claims and testosterone claims

Here's the honest answer: the confident protocols circulating online about the best time to take IGF LR3 were not derived from research. They were reverse-engineered from bodybuilding folklore about insulin timing and then dressed in pharmacological language. The same applies to the testosterone claim, which survives because IGF-1 sounds anabolic and testosterone is anabolic, and that's the entire logical chain. Long R3 IGF-1 is a cell-culture reagent and a preclinical research tool with a well-characterised structure and a genuinely interesting binding-protein story. Everything beyond that is invention, and invention is exactly what compromises a dataset.

Our catalogue listing for IGF-1 LR3 documents batch identity and purity, and the analytical records for our compounds are published in our certificate of analysis library so researchers can verify what they're working with before it reaches the bench. Details on our facility and shipping are on our location page, and the wider research peptide catalogue is organised the same way, with small-batch synthesis and exact sequence verification behind every listing.

Everyone typing the best time to take IGF LR3 into a search bar is really asking something else: will this do what I've read it does, and how fast. The structural biology answers neither question, and the honest reading of that silence is informative in itself. A molecule engineered to shrug off its binding proteins was built to solve a cell-culture problem, not a training one. The binding proteins it evades are the same ones evolution installed to keep IGF-1 signalling under tight control, which is a design detail worth sitting with before treating any of this as settled.

References

Peer-reviewed sources on IGF-1 LR3 indexed in PubMed, listed for research context. Real Peptides supplies IGF-1 LR3 for laboratory research use only.

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943. doi:10.1152/ajpendo.00259.2024
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's disease : JAD, 2025. PMID 39610283. doi:10.1177/13872877241299056
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023. PMID 37261455. doi:10.1007/s00253-023-12606-0
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023. PMID 37114757. doi:10.1017/S2040174423000090
Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995. PMID 7561636. doi:10.1677/joe.0.1460247

Questions

No published human evidence shows that IGF-1 LR3 increases testosterone. It signals through the IGF-1 receptor and has no reported androgen receptor affinity. Cultured Leydig cell research suggests IGF-1 signalling can amplify LH-stimulated steroidogenesis, but that mechanism observation has never been translated into a controlled human outcome for this analogue.

There is no defined answer, because the timescale depends on the endpoint measured. In vitro, IGF-1 receptor phosphorylation occurs within minutes; protein synthesis shifts register over hours; tissue-level endpoints in preclinical animal models accumulate over weeks. Without naming the measured endpoint, the question has no meaningful answer.

Receptor-level activity begins within minutes of exposure in cell culture, since IGF-1 receptor autophosphorylation and PI3K/Akt signalling are fast events. Observable changes in tissue-level measures in preclinical study models take weeks to exceed measurement noise. No human timeline exists because Long R3 IGF-1 has never been trialled in people.

Native IGF-1 is a 70-amino-acid chain of roughly 7.6 kDa. Long R3 IGF-1 is 83 amino acids and roughly 9.1 kDa, carrying a 13-residue N-terminal extension plus arginine substituted for glutamic acid at position 3. Both changes sharply reduce binding-protein affinity, which extends biological availability.

Research-grade IGF-1 LR3 is supplied to researchers, laboratories, and institutions for in vitro and preclinical work only. It is not an approved drug product in any jurisdiction and is never sold for human or veterinary consumption. Purchasers are responsible for compliance with the regulations governing research materials in their own territory.

Pricing varies widely by vial quantity, verified purity, and supplier, so current figures are best checked directly on a catalogue page rather than quoted generally. The meaningful cost variable isn't the headline price, it's whether the batch ships with analytical documentation confirming identity and purity.

Lyophilised peptides are generally held frozen at around minus 20 degrees Celsius for long-term stability, with reconstituted solutions refrigerated at 2 to 8 degrees Celsius. Protect vials from light and repeated freeze-thaw cycles. Temperature excursions cause protein denaturation that is invisible to the eye and undetectable without analytical testing.

The research literature identifies two principal concerns. IGF-1 cross-reacts with the insulin receptor at sufficient concentration, which is why hypoglycaemia is a documented risk in the labelling of approved recombinant IGF-1 products. Separately, IGF-1 is a potent mitogen, and epidemiological work has examined associations between elevated circulating IGF-1 and proliferative disease risk.

Yes. The World Anti-Doping Agency prohibits IGF-1 and its analogues under the S2 category covering peptide hormones, growth factors and related substances, and that prohibition applies both in and out of competition. Athletes subject to anti-doping testing should treat any IGF-1 analogue as a prohibited substance.

Request the batch-specific certificate of analysis and check two things: HPLC purity percentage and mass spectrometry confirmation against the expected molecular weight of the 83-residue sequence. A certificate that reports only a purity figure without mass confirmation cannot rule out a closely related but incorrect peptide.

That question assumes a human use case that doesn't exist for this compound. Long R3 IGF-1 is a research chemical with no approved human indication and no published administration guidance of any kind. Its reduced binding-protein affinity also means its biological availability is described as prolonged rather than event-synchronised.

No. Photographic comparisons carry no control arm, no blinding, no assay data, and no record of diet, training load, hydration, or concurrent compounds. In almost every circulating example, multiple substances were involved. Photographs describe an appearance at two moments, not a causal effect of any single molecule.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA